Overview of systematic reviews of therapeutic ranges: methodologies and recommendations for practice

Cooney, Lewis; Loke, Yoon K.; Golder, Su; Kirkham, Jamie J; Jorgensen, Andrea; Sinha, Ian; Hawcutt, Daniel B

doi:10.1186/s12874-017-0363-z

Cited by 26 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In that regard, the optimal efficacy of a drug at the infected site is when the drug concentration measured over a period of time lies within a certain therapeutic range [18], [19]. The therapeutic range of a drug is the range in which the drugs are usually expected to achieve efficacy [20] with the lower and upper boundary called as the least effective concentration (LEC) and the maximum effective concentration (MEC), respectively. When an MC-based TDD is used for drug delivery, the drugrelease task is such that each nanomachine will release some amount of drug and a cumulative concentration of the drug is anticipated at the infected site.…”

Section: Introductionmentioning

confidence: 99%

A Simultaneous Drug Release Scheme for Targeted Drug Delivery Using Molecular Communications

2020

View full text Add to dashboard Cite

In this paper, we consider drug release-time issue in molecular communication-based targeted drug delivery (MC-based TDD) systems. Typically, a trigger source sends out a signal to multiple nanomachines to indicate them when to release the drugs in a simultaneous manner. However, under a practical setting where the nanomachines are located at unequal distances from the source and the propagation delay of an MC channel is proportional to the third power of distance, the trigger signal may arrive at different times causing the nanomachines to release the drugs in a nonsimultaneous manner. This causes release-time errors. Therefore, we propose a simultaneous drug-release scheme to determine the precise time to emit the trigger signal, taking into account the propagation delay information to minimize the release-time errors. Using both analytical and simulation approach, we demonstrate the effectiveness of the proposed scheme in reducing the release-time errors, highlighting its robustness to large propagation delays. Additionally, we show that the analytical model is in good agreement with the simulation. INDEX TERMS Molecular communication, nanomedicine, nanonetworks, release-time, targeted drug delivery. TANIA ISLAM received the B.Sc. Engg. degree in CSE from Patuakhali Science and Technology University (PSTU), in 2012, the M.Sc. degree in CS from Jahangirnagar University (JU), in 2014, and the M.Sc. Engg. degree in CSE from Khulna University (KU), Bangladesh, in 2018. She is currently pursuing the Ph.D. degree in information and communication engineering with Kyungpook

show abstract

Section: Introductionmentioning

confidence: 99%

A Simultaneous Drug Release Scheme for Targeted Drug Delivery Using Molecular Communications

2020

View full text Add to dashboard Cite

show abstract

“…Currently available quality assessment tools do not specifically address drug concentration-effect studies [16], thus criteria for quality assessment were adapted from a previously published meta-analysis of Ulrich et al concerning the concentration-therapeutic effect relationship of haloperidol in adults [17]. As the current systematic review covers different types of psychotropic drugs with a broad range of indications, not all criteria of the total score as used by Ulrich et al were applicable.…”

Section: Quality Assessment Of Therapeutic Drug Monitoringmentioning

confidence: 99%

“…Many studies failed to perform standardized sampling, including sampling with respect to steady state and administration time. Therefore, there is a need for an accepted tool for the appraisal of drug concentration-effect studies [10,16]. The assessment criteria proposed by this report could serve as a starting point, hopefully reducing the heterogeneity observed to date, and permitting meta-analyses.…”

Section: Research Recommendations To Support Tdm In Childand Adolescementioning

confidence: 99%

Psychotropic drug concentrations and clinical outcomes in children and adolescents: a systematic review

Kloosterboer

Vierhout

Stojanova

et al. 2020

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Introduction: The use of psychotropic drugs in children and adolescents is widespread but associated with suboptimal treatment effects. Therapeutic drug monitoring (TDM) can improve safety of psychotropic drugs in children and adolescents but is not routinely performed. A major reason is that the relationship between drug concentrations and effects is not well known. Areas covered: This systematic review evaluated studies assessing the relationship between psychotropic drug concentrations and clinical outcomes in children and adolescents, including antipsychotics, psychostimulants, alpha-agonists, antidepressants, and mood-stabilizers. PRISMA guidelines were used and a quality assessment of the retrieved studies was performed. Sixty-seven eligible studies involving 24 psychotropic drugs were identified from 9,298 records. The findings were generally heterogeneous and the majority of all retrieved studies were not of sufficient quality. For 11 psychotropic drugs, a relationship between drug concentrations and side-effects and/or effectiveness was evidenced in reasonably reported and executed studies, but these findings were barely replicated. Expert opinion: In order to better support routine TDM in child-and adolescent psychiatry, future work must improve in aspects of study design, execution and reporting to demonstrate drug concentrationeffect relationships. The quality criteria proposed in this work can guide future TDM research. Systematic review protocol and registration PROSPERO CRD42018084159 ARTICLE HISTORY

show abstract

“…The concern about these values is due to the fact that the recommended dose is 1 to 2 g of the herbal product 2 to 3 times a day [34]. Ingesting a greater amount can cause a dose higher than the therapeutic range established for it (dosage range, or blood plasma or serum concentration usually expected to achieve the desired therapeutic effect) [41]. This can cause the side effects appearance [42].…”

Section: Table-3: Labeling Percentage Of the Analyzed Samples Of Eachmentioning

confidence: 99%

Quality Control of a Boldo Tisanes Brand Commercialized in Costa Rica Following the Central American Technical Regulation for Natural Products

Stefanny¹,

Omar²,

Gloriana³

et al. 2020

SJMPS

View full text Add to dashboard Cite

One of the medicinal species used as raw material for the tisanes preparation is the boldo leaf (Peumus boldus). This plant is commonly used as treatment for a variety of conditions, such as digestive and hepatobiliary disorders. It is traditionally known for its choleretic, cholagogue, diuretic, and digestive properties, among others. The objectives of this work were to evaluate the quality of four batches of boldo tisanes of a brand commercialized in Costa Rica through various physicochemical and microbiological tests established in the Central American Technical Regulation (RTCA) 11.03.56.09, and to identify the reproducibility of the quality parameters for the four batches employed. For this reason, the following tests were done: labeling, organoleptic characteristics, foreign matter determination, minimum fill, lead limit, arsenic limit, loss on drying, total ash, microbial enumeration, and specific microorganisms (E. coli and Salmonella sp). The four analyzed batches were in compliance for all assays, except the labeling test, since in all cases only 2 of the 4 items established for the primary packaging (batch number and expiration date) and 3 of the 19 items indicated for the secondary packaging (qualitative-quantitative composition, interactions, and adverse effects) were not found. In addition, the batch 2 had a browner color compared to the others, not complying with the organoleptic test specifications, specifically the color. This is reaffirmed by obtaining a greater percentage of branches in its composition during the foreign matter test. For these reasons, greater controls must be made on the raw material used for the product preparation to achieve reproducibility between the quality characteristics required for the different batches.

show abstract

Overview of systematic reviews of therapeutic ranges: methodologies and recommendations for practice

Cited by 26 publications

References 34 publications

A Simultaneous Drug Release Scheme for Targeted Drug Delivery Using Molecular Communications

A Simultaneous Drug Release Scheme for Targeted Drug Delivery Using Molecular Communications

Psychotropic drug concentrations and clinical outcomes in children and adolescents: a systematic review

Quality Control of a Boldo Tisanes Brand Commercialized in Costa Rica Following the Central American Technical Regulation for Natural Products

Contact Info

Product

Resources

About